Advertisement
Home »

Perioperative Nivolumab Boosts Event-Free Survival in NSCLC

Oct 26, 2023

REFERENCES & ADDITIONAL READING

Provencio M, Nadal E, González-Larriba JL, et al. N Engl J Med. 2023;389:504-513. DOI: 10.1056/NEJMoa2215530

 

Forde PM, Spicer J, Lu S, et al. N Engl J Med. 2022;386:1973-1985. DOI: 10.1056/NEJMoa2202170

 

Cascone T, Awad M, Spicer J, et al. CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II-IIIb NSCLC. Abstract LBA1, ESMO 2023, 20-24 October, Madrid, Spain.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement